Molecular Genetics of Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
NorthShore University HealthSystem
ClinicalTrials.gov Identifier:
NCT00006418
First received: October 25, 2000
Last updated: April 1, 2014
Last verified: November 2005
  Purpose

This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes that predispose people to schizophrenia.


Condition Intervention
Schizophrenia
Procedure: DNA collection

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by NorthShore University HealthSystem:

Estimated Enrollment: 10800
Study Start Date: September 2003
Estimated Study Completion Date: August 2007
Detailed Description:

Each site will recruit individuals in a large geographic area, and use efficient ascertainment strategies and assessment procedures in order to maximize the number collected. Subjects thought to have schizophrenia will be assessed by personal and family interviews and a review of medical records. Diagnoses will be made by consensus best-estimate procedures. Blood specimens will be obtained from all individuals with schizophrenia or schizoaffective disorder plus their available parents and also the control individuals. A clinical self-assessment will be administered to each control subject. The assessment will include validated self-assessments of lifetime major depression, anxiety disorders, and substance use, and self-reported history of bipolar or psychotic symptoms. Permanent cell lines will be created and DNA extracted at the NIMH-sponsored Center for Genetic Studies. At the end of the four-year project period, biological materials and blinded pedigree and clinical data will be made available to the scientific community for genetic studies of schizophrenia and related disorders. The control sample will, however, be released in a staggered fashion, twice during each fiscal year, to start during the 2nd year of recruitment. The informed consent for controls includes consent for specimens to be used in research on the genetics of any medical disorder. In years 3 and 4, we will undertake association analyses. Power analyses suggest that this study will have excellent power to detect loci associated with genes with relatively small etiologic effects. Data derived from this study will potentially have applications for the treatment and prevention of schizophrenia.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals thought to have schizophrenia or schizoaffective disorder, be the parent of such an individual, or be in the matched control group of unrelated individuals not thought to have schizophrenia or schizoaffective disorder

Exclusion Criteria:

  • Unable to give informed consent to all aspects of the study
  • Psychotic disorder judged to be secondary to substance use, psychotic disorder that appears to be secondary to a known medical or neurological disorder, or severe mental retardation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006418

Locations
United States, California
University of California, Irvine
Irvine, California, United States, 92697
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Illinois
Evanston Northwestern Healthcare Research Institute
Evanston, Illinois, United States, 60201
United States, Iowa
University of Iowa College of Medicine
Iowa City, Iowa, United States, 52242
United States, Louisiana
Louisiana State University Health Sciences Center
New Orleans, Louisiana, United States, 70112
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63128
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Pennsylvania
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States, 19104
Australia, Queensland
University of Queensland
Brisbane, Queensland, Australia, 4029
Sponsors and Collaborators
NorthShore University HealthSystem
  More Information

Additional Information:
Publications:
O'Donovan MC, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Giegling I, Hartmann AM, Möller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Adolfsson R, Osby U, Terenius L, Jönsson EG, Cichon S, Nöthen MM, Gill M, Corvin AP, Rujescu D, Gejman PV, Kirov G, Craddock N, Williams NM, Owen MJ; Molecular Genetics of Schizophrenia Collaboration. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol Psychiatry. 2009 Jan;14(1):30-6. Epub 2008 Sep 23.

ClinicalTrials.gov Identifier: NCT00006418     History of Changes
Other Study ID Numbers: R01 MH59571, R01MH059571, R01 MH59571, R01 MH59588, R01 MH60870, R01 MH59565, R01 MH59566, R01 MH60879, R01 MH59586, R01 MH61675, R01 MH59587, DNBBS 7G-GRR
Study First Received: October 25, 2000
Last Updated: April 1, 2014
Health Authority: United States: Federal Government

Keywords provided by NorthShore University HealthSystem:
Schizophrenia
Genetics

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on August 28, 2014